Drug Interaction Report

MONITOR: Coadministration with weak inducers of CYP450 3A4 may reduce the plasma levels and effects of lazertinib, which is primarily metabolized by the isoenzyme. In a phase 1 study of healthy adult participants, concomitant use of the strong CYP450 3A4 inducer rifampin reduced the peak plasma concentration (Cmax) and systemic exposure (AUC) of lazertinib by 72% and 83%, respectively. Likewise, a pharmacokinetic model predicted that concomitant use with the moderate CYP450 3A4 inducer efavirenz would decrease lazertinib's steady state Cmax and AUC by at least 32% and 44%, respectively. Clinical data with less potent CYP450 3A4 inducers are not available.

MANAGEMENT: The potential for diminished pharmacologic effects of lazertinib should be considered if coadministration with a weak CYP450 3A4 inducer is clinically necessary. An alternative concomitant medication with no potential to induce CYP450 3A4 may be required.

MONITOR: Isolated case reports have suggested that the ingestion of alcohol during griseofulvin therapy may rarely cause disulfiram-like reactions, flushing, tachycardia, or increased effects of alcohol. The mechanism is unknown.

MANAGEMENT: Patients should be advised of the possibility of increased adverse effects or a disulfiram-like reaction.